GOSS Earnings

GOSS reported its FY2025Q2 earnings on 2025-08-05, showcasing a revenue of 11.49M against an estimate of 5.41M, resulting in a 112.41% surprise. The EPS was -0.17, surpassing the expected -0.18 by 5.56%. The stock experienced a -8.33% price change on the earnings day and a -19.68% change over the next five days, reflecting market reactions to the results.

Following GOSS's FY2025Q2 earnings announcement on 2025-08-05, the stock price moved by -8.33% on the day of the release. Over the subsequent five days, it saw a -19.68% change. Historically, GOSS's stock price tends to shift by an average of 5.79% in the 10 days leading up to earnings and 0.18% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate GOSS's annual revenue to reach 5.78M, while the EPS is projected at -0.17. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GOSS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GOSS's stock price typically moves by 5.79% in the 10 days before its earnings and 0.18% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.17 and revenue of 5.78M.

The earnings call summary lacks explicit financial performance details, with no mention of revenue, margins, or cash flow. Regulatory and commercialization plans for seralutinib suggest potential growth, but regulatory and financial risks introduce uncertainties. The absence of clear shareholder return plans and unclear management responses in the Q&A section further support a neutral outlook. Without a market cap, the stock's reaction is uncertain, leading to a neutral sentiment rating.